Pharmaceutical

Reset Pharma partners with Filament to license psilocybin drug

Reset Pharma has entered a licensing agreement with Filament for psilocybin drug PEX010, designed for treating demoralisation syndrome.

Sep 1, 2023 - 20:00
Reset Pharma partners with Filament to license psilocybin drug
Reset Pharma has entered a licensing agreement with Filament for psilocybin drug PEX010, designed for treating demoralisation syndrome.
Read the original article

Tags:

Previous Article

The changing of the guard is expected in the Crohn’s disease marketplace

Next Article

Huadong enters licence deal for MC2 Therapeutics’ Wynzora cream

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Biostax and Immgenuity to expedite HIV immunotherapies development

Biostax and Immgenuity to expedite HIV immunotherapies ...

Aug 30, 2023

Bayer’s not breaking up. At least not yet

Bayer’s not breaking up. At least not yet

Mar 6, 2024

Amneal files again for FDA approval of first dihydroergotamine autoinjector

Amneal files again for FDA approval of first dihydroerg...

Nov 23, 2024